Search Results

CHOLESTEROL: Reagent kit intended for the quantitative determination of Cholesterol in human serum. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood, of lipid and lipoprotein metabolism disorders.

HDL-Cholesterol: Reagent kit intended for the quantitative determination of high-density lipoprotein in human serum. Measurements are used in the diagnosis and treatment of lipid disorders mellitus), atherosclerosis, and various liver and renal diseases.

LDL-Cholesterol: Reagent kit intended for the quantitative determination of low-density lipoprotein in human serum. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.

TRIGLYCERIDES: Reagent kit intended for the quantitative determination of triglycerides (neutral fat) in human serum. Measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.

CHOLESTEROL: The Cholesterol Oxidase peroxidase (CHOD-PAP) enzymatic method is used. The cholesterol esterase enzyme catalyzes the hydrolysis of cholesterol and free fatty and free fatty acids. Free cholesterol, including that originally present in the sample, is then oxidized by the enzyme cholesterol oxidase (CHOD) to cholest-4-en-3-one, by using molecular oxygen as the electron acceptor and concurrently producing hydrogen peroxide (H2O2). The H2O2 produced is then used in a subsequent chromogenic oxidative coupling reaction, catalyzed by the enzyme peroxidase, in the presence of a redox indicator system, which leads to the formation of a colored compound, absorbing light at 550 nm. The increase in absorbance is directly proportional to the cholesterol concentration in the sample.

HDL-Cholesterol: The Accelerator Selective Detergent method is applied. The determination of HDL-Cholesterol is based on the following reactions: LDL, VLDL, and chylomicrons are neutralized by the combined action of the enzymes Cholesterol Oxidase, Peroxidase, accelerators and N,N-bis-(4-sulfobutyl)-m-toluidine-disodium (DSBmT). HDL remaining in the sample is disrupted by the action of a selective detergent and cholesterol is converted to △4 Cholestenone by the enzymatic action of Cholesterol Esterase and Cholesterol Oxidase, with the subsequent production of H2O2, which reacts with DSBmT and 4-aminoantipyrine in the presence of Peroxidase to a colored complex that absorbs light at 590 nm. The absorbance measured is proportional to the concentration of HDL-Cholesterol in the sample.

LDL-Cholesterol: The Selective Detergent method is applied. The method is in a two-reagent format and depends on the properties of a unique detergent. The first detergent solubilizes only the non-LDL lipoprotein particles. The cholesterol released is consumed by cholesterol esterase and cholesterol oxidase in a non-color forming reaction. The second detergent solubilizes the remaining LDL particles, and a chromogenic coupler allows for color formation. The enzyme reaction with LDL-Cholesterol in the presence of the coupler at 590 nm produces color that is proportional to the amount of LDL cholesterol present in the sample.

TRIGLYCERIDES: The enzymatic glycerol-3-phosphate-peroxidase (GPO-POD) method is used. The method enzymatically hydrolyzes by lipase to free fatty acids and glycerol is phosphorylated by adenosine triphosphate (ATP) with glycerokinase (GK) to produce glycerol-3-phosphate and adenosine diphosphate (ADP). Glycerol-3-phosphate-oxidase oxidizes glycerol-3-phosphate to dihydroxyacetone phosphate and H2O2. The catalytic action of peroxidase (POD) forms quinoneimine from H202, aminoantipyrine, and Dihydrate (N-Ethyl-N-(2hydroxy-3-sulfopropyl)-m-toluidine (TOOS). The absorption change at 550 nm is proportional to the triglycerides concentration in the sample.

Here's a breakdown of the acceptance criteria and the study information for the Medicon Hellas Cholesterol, HDL-Cholesterol, LDL-Cholesterol, and Triglycerides test systems, based on the provided document:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are generally established by comparison to legally marketed predicate devices and alignment with clinical laboratory guidelines (CLSI). The document presents a clear comparison in the "Device Comparison Table" sections. For this summary, I'll focus on the key performance indicators for each analyte.

CHOLESTEROL

HDL-Cholesterol

LDL-Cholesterol

TRIGLYCERIDES

2. Sample size used for the test set and the data provenance

• Accuracy (Method Comparisons):

  • A minimum of 75 leftover specimens.
  • For the specific analytes:
    • CHOLESTEROL: 93 human serum samples
    • HDL-Cholesterol: 141 human serum samples
    • LDL-Cholesterol: 107 human serum samples
    • TRIGLYCERIDES: 163 human serum samples
  • Data Provenance: The document states "left-over specimens," implying retrospective use of clinical samples. The country of origin is not explicitly stated, but the company is Medicon Hellas, S.A. based in Greece, and testing was performed at the company premises.

• Precision/Reproducibility:

  • Three human serum pools for Cholesterol and Triglycerides.
  • Two pools for HDL-Cholesterol.
  • Four pools for LDL-Cholesterol.
  • Each sample was tested for 20 testing days, two different runs, and two replicate measurements per run (morning and afternoon run), for a total of 80 results per level concentration (e.g., for Cholesterol, 3 pools * 80 results/pool = 240 results).
  • Data Provenance: Human serum pools, likely prepared in-house or acquired for the study.

• Linearity:

  • 11 to 13 levels per analyte, prepared by dilution of a human serum pool.
  • Each level was tested in 4 replicates.
  • Data Provenance: Human serum pool.

• Analytical Specificity / Interference:

  • Serum pools at low and high levels of each analyte.
  • Each measurement of the blank and the sample containing the interferent was repeated at least 5 times.
  • Data Provenance: Serum pools.

• Detection Limit:

  • LoB: 5 blank serum samples measured in 4 replicates for 3 days (total of 60 measurements).
  • LoD: 5 low-level samples measured in 4 replicates for 3 days (total of 60 measurements).
  • LoQ: 10 samples that span the low end of linearity, measured 5 times each day for 3 days (total of 150 measurements).
  • Data Provenance: Serum samples.

• Stability and Calibration Frequency:

  • Two fresh serum pools and two serum-based commercial controls.
  • Measurements were repeated in triplicate at regular time points.
  • Data Provenance: Serum pools and commercial controls.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided in the document. The ground truth for performance studies like those described (method comparison, precision, linearity, interference, detection limits) for in vitro diagnostic (IVD) devices like these typically involves established reference methods or highly accurate comparative analyzers, rather than expert human interpretation of results. The document states that the performance of the Medicon Hellas reagents was compared with "comparator methods" (Beckman Coulter reagents on AU400, Abbott Diagnostics reagents on Architect c8000), which serve as the reference for ground truth in these types of analytical performance studies. The qualifications of the operators performing these studies are not specified.

4. Adjudication method for the test set

This information is not applicable and therefore not provided. Adjudication methods (e.g., 2+1, 3+1) are typically used in studies where human interpretation of complex data (like medical images) is involved and a consensus is needed to establish ground truth. For quantitative chemical assays, the ground truth is established by the highly precise and accurate measurement of reference methods or predicate devices.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This information is not applicable and therefore not provided. MRMC studies are specific to evaluating diagnostic devices where human readers interpret medical cases, often with and without AI assistance (e.g., radiology AI). The Medicon Hellas devices are in vitro diagnostic reagents for quantitative chemical measurements in serum, not image-based diagnostic tools that require human "readers" in the context of an MRMC study.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This concept is not applicable in the traditional sense for these in vitro diagnostic reagents. These devices are chemical assays that produce a quantitative numerical output (e.g., cholesterol level in mg/dL). There isn't an "algorithm" making a diagnostic interpretation independently in the way AI software would. The device is the standalone measurement system. Its performance is evaluated independently through analytical studies (precision, linearity, accuracy against reference methods, etc.). The results are then read and interpreted by a human clinician.

7. The type of ground truth used

The ground truth for the analytical performance studies (precision, linearity, interference, detection limits, and method comparison) was established against:

• Reference Methods/Predicate Devices: For method comparison, the device's performance was compared against established comparator methods (Beckman Coulter reagents on AU400 and Abbott Diagnostics reagents on ABBOTT Architect c8000). The document explicitly states these as the comparators.
• A Priori Values/Established Standards: For linearity, precision, and detection limits, the ground truth is based on the known concentrations of prepared samples (e.g., serially diluted pools, spiked samples, blank serum) and statistical analysis according to CLSI guidelines.
• Traceability to Reference Methods/Materials: For Cholesterol and Triglycerides, traceability is to Gas-chromatography-isotope dilution mass spectrometry (GC-IDMS). For HDL-Cholesterol and LDL-Cholesterol, traceability is to the Abell-Kendall (AK) reference method.

8. The sample size for the training set

This information is not applicable and therefore not provided. These are chemical reagent kits, not machine learning (AI/ML) models that require a "training set" in the computational sense. The development of such reagents involves chemical and enzymatic research and optimization, often tested with various batches and concentrations of samples during R&D. The studies described in this document are for validation and verification of the final device, not for "training" an algorithm.

9. How the ground truth for the training set was established

As noted above, the concept of a "training set" with ground truth established in the AI/ML sense is not applicable to these chemical reagent devices. The "ground truth" for evaluating the analytical performance of the developed reagent kits is established through the reference methods and standardized protocols described in section 7.

Ask a specific question about this device